DUPONT MERCK GENERIC CIMETIDINE WILL BE DISTRIBUTED BY ENDO LABS
DUPONT MERCK GENERIC CIMETIDINE WILL BE DISTRIBUTED BY ENDO LABS following the expiration on May 17 of SmithKline Beecham's Tagamet patent. DuPont Merck received tentative ANDA approvals on April 29 for 200 mg, 300 mg and 400 mg tablet strengths of the anti-ulcer medication. On May 3, the firm added an approval for an 800 mg tablet. The company announced the establishment of its generic drug subsidiary Endo in March ("The Pink Sheet" March 28, T&G-3).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth